Literature DB >> 4006348

Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.

W E Strauss, T Egan, K M McIntyre, A F Parisi.   

Abstract

Although congestive heart failure has been reported with the combination of a beta blocker and either verapamil or nifedipine, it has not previously been reported for combination therapy that includes diltiazem. The following case documents the occurrence of clinical congestive failure in a patient with baseline left ventricular dysfunction and severe angina pectoris. Although the patients had tolerated propranolol therapy for years without difficulty, and high-dose diltiazem monotherapy with an excellent clinical response, the combination of diltiazem and propranolol resulted in the development of congestive heart failure. Thus, although generally well tolerated, given the suitable scenario of reduced left ventricular function, the combination of diltiazem and a beta blocker may adversely affect left ventricular performance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006348     DOI: 10.1002/clc.4960080612

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

3.  Patterns and characteristics of polypharmacy among elderly residents in Danish nursing homes.

Authors:  Jacob Astorp; Mimoza Gjela; Pernille Jensen; Rasmus D Bak; Parisa Gazerani
Journal:  Future Sci OA       Date:  2020-05-29

Review 4.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.